Even the highest-quality companies are not immune to market selloffs.
In fact, periods of uncertainty often see investors pull back from even the most established names. While that can be uncomfortable in the short term, it can also create opportunities to buy leading businesses at more attractive prices.
Here are three ASX blue chips that have fallen heavily and could be worth a closer look.
Cochlear Ltd (ASX: COH)
The first ASX blue chip that could be too cheap to ignore is Cochlear.
The hearing solutions company recently disappointed the market with a softer-than-expected result, driven in part by a slower rollout of its new Nexa system and margin pressure from product mix.
While this has weighed on sentiment, it does not change Cochlear's long-term position as a global leader in implantable hearing devices.
Demand for hearing solutions continues to grow due to ageing populations and increased awareness. Cochlear also benefits from a large installed base, which generates recurring revenue through upgrades and servicing.
If the company can execute on its product rollout and return to stronger growth, the current weakness could prove temporary.
CSL Ltd (ASX: CSL)
Another ASX blue chip that may be worth considering is CSL.
The biotech giant's shares have fallen sharply following a soft result and the unexpected CEO transition, which has created uncertainty around its near-term outlook.
The key issue has been weaker-than-expected performance in its CSL Behring division, particularly in immunoglobulin, alongside slower margin recovery than the market had anticipated.
However, CSL still operates in global healthcare markets with strong demand and high barriers to entry. Its therapies address serious medical conditions, and long-term growth drivers remain intact.
While challenges remain, the company's track record and market position suggest it has the capability to work through this period and return to more consistent growth.
James Hardie Industries plc (ASX: JHX)
A third ASX blue chip that could be trading at an attractive level is James Hardie Industries.
The building materials company has been under pressure due to concerns about housing market weakness, particularly in the United States.
Slower construction activity can weigh on demand for its fibre cement products, which has led to more cautious sentiment from investors.
However, James Hardie remains a leader in its category, with strong brand recognition and a history of gaining market share over time.
When housing activity eventually recovers, the company could be well placed to benefit. In the meantime, it continues to focus on innovation and expanding its product offering.
For investors willing to look beyond the near-term uncertainty, this could make it an interesting option at current levels.
The post Are these ASX blue chips now too cheap to ignore? appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in CSL and Cochlear. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026